Target intelligence / Profile preview

Poly(ADP-ribose) polymerase and cellular thiol-dependent redox systems (PARP/Thiol-Redox)

Target
PARP/Thiol-Redox
Molecular classification
Enzyme, Metabolic pathway, DNA repair protein
01

Overview

Poly(ADP-ribose) polymerase (PARP) and cellular thiol-dependent redox systems, including the glutathione and thioredoxin pathways, constitute a critical axis in the maintenance of genomic integrity and redox homeostasis. PARP1, the most prominent member of the PARP family, functions as a molecular sensor of DNA damage, facilitating the repair of single-strand breaks via the base excision repair pathway (UniProt P09874). Thiol-dependent systems are the primary cellular defense against oxidative stress, utilizing reducing equivalents to neutralize reactive oxygen species and maintain protein function (PubMed PMID: 28235563). The synergy between these systems is therapeutically significant; PARP inhibition leads to the accumulation of DNA damage, while the depletion of thiol-dependent antioxidants increases the burden of oxidative lesions. This dual-targeting approach is particularly effective in oncology, where it can induce synthetic lethality in homologous recombination-deficient cells or trigger parthanatos, a form of programmed cell death driven by PARP overactivation and NAD+ depletion (PubMed PMID: 15548208). Clinical applications primarily focus on PARP inhibitors like olaparib and niraparib, often in the context of BRCA-mutated cancers, with emerging research exploring the modulation of redox systems to enhance therapeutic efficacy (PubChem CID 23667635).

Other names
PARPPoly(ADP-ribose) polymeraseGlutathione systemThioredoxin systemGSH/Trx systemsPARP-1
02

Mechanism of action

Inhibition of PARP-mediated DNA repair and disruption of thiol-dependent antioxidant defenses to induce genomic instability and oxidative stress-induced cell death.

03

Biological functions

DNA repairRedox homeostasisApoptosisCell deathMetabolism
04

Disease associations

CancerNeurodegenerative diseaseInflammationIschemia-reperfusion injury
05

Safety considerations

MyelosuppressionAnemiaNeutropeniaGastrointestinal toxicityFatigueRisk of secondary malignancies
06

Interacting drugs

Olaparib

6 more in the full profile.

07

Biomarkers

BRCA1 mutationBRCA2 mutationHomologous recombination deficiency (HRD)Glutathione levelsReactive oxygen species (ROS) levels

Beyond the preview

Go deeper on Poly(ADP-ribose) polymerase and cellular thiol-dependent redox systems (PARP/Thiol-Redox).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Poly(ADP-ribose) polymerase and cellular thiol-dependent redox systems (PARP/Thiol-Redox).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call